Nurix Therapeutics Inc Revenue Growth Rates (NRIX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nurix Therapeutics Inc   (NASDAQ: NRIX)
 

NRIX's Revenue Growth by Quarter and Year

Nurix Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NRIX/growth
https://api.csimarket.com/api/v1/companies/NRIX/fundamentals
https://api.csimarket.com/api/v1/companies/NRIX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NRIX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter November -
3rd Quarter August 673.06
2nd Quarter May 9.04
1st Quarter February 6.25
FY 688.35

NRIXs Annual Revenue
Nurix Therapeutics Inc 's Revenue in the fiscal year 2025 $ 83.98 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2024 $ 54.55 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2023 $ 76.99 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2022 $ 38.63 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2021 $ 29.75 millions




NRIX Revenue third quarter 2026 Y/Y Growth Comment
Nurix Therapeutics Inc achieved in the third quarter 2026, above Company average Revenue surge of 8430.6% year on year, to $ 673.06 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue growth. While Nurix Therapeutics Inc ' s Revenue doubling of 8430.6% ranks overall at the positon no. 3021 in the third quarter 2026.


NRIX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter November -
3rd Quarter August 8430.6 %
2nd Quarter May -79.48 %
1st Quarter February -66.12 %
FY   -

Financial Statements
Nurix Therapeutics Inc 's third quarter 2026 Revenue $ 673.06 millions NRIX's Income Statement
Nurix Therapeutics Inc 's third quarter 2025 Revenue $ 7.89 millions Quarterly NRIX's Income Statement


NRIX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter November -
3rd Quarter August 7345.4 %
2nd Quarter May 44.64 %
1st Quarter February -53.98 %
FY (Year on Year)   -


Back to NRIX Growth rate Comparisons >> Back to NRIX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #414
Overall #3021

Revenue Y/Y Growth Statistics
High Average Low
738.76 % 61.49 % -58.4 %
(Aug 31 2026)   (May 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #414
Overall #3021
Revenue Y/Y Growth Statistics
High Average Low
738.76 % 61.49 % -58.4 %
(Aug 31 2026)   (May 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nurix Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
7342.93 % 259.89 % -82.4 %
(Aug 31 2026)  


NRIX's III. Quarter Q/Q Revenue Comment
Nurix Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 7345.4%, to $ 673.06 millions, from $9.04 millions in the second quarter.
NRIX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Nurix Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 7.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #5
Overall #7
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #5
Overall #7
Revenue Q/Q Growth Statistics
High Average Low
7342.93 % 259.89 % -82.4 %
(Aug 31 2026)  


NRIX's III. Quarter Q/Q Revenue Comment
Nurix Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 7345.4%, to $ 673.06 millions, from $9.04 millions in the second quarter.
NRIX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Nurix Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 7.


Nurix Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Aug 31 2026)		 12 Months Ending (May 31 2026) 12 Months Ending (Feb 28 2026) 12 Months Ending (Nov 30 2025) 12 Months Ending (Aug 31 2025)
Cumulative Revenue 12 Months Ending $ 701.94
Y / Y Revenue Growth (TTM) 738.76 %
Year on Year Revenue Growth Overall Ranking # 362
Seqeuential Revenue Change (TTM) 1809.2 %
Seq. Revenue Growth (TTM) Overall Ranking # 3021


Cumulative Revenue growth Comment
With 738.76% annual Revenue growth, Nurix Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Aug 31 2026.

In the Healthcare sector 91 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 358 to 362.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 92
Overall # 362

Revenue TTM Y/Y Growth Statistics
High Average Low
738.76 %
 61.49 %
-58.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 414
S&P 500 # 3021
Cumulative Revenue growth Comment
With 738.76% annual Revenue growth, Nurix Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Aug 31 2026.

In the Healthcare sector 91 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 358 to 362.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 92
Overall # 362

Revenue TTM Y/Y Growth Statistics
High Average Low
738.76 %
61.49 %
-58.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 414
S&P 500 # 3021




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NRIX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Aug 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Aug 31 2026
Nurix Therapeutics Inc 8,426.27%$ 8,426.273 millions


About Nurix Therapeutics Inc Revenue Growth Rates (NRIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nurix Therapeutics Inc (CIK 1549595).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001549595-26-000049
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nurix Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.